Pliant Therapeutics, Inc.

Scott Turner

Martin Decaris

Eric Lefebvre

Chun Chen

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Dosage forms and regimens for amino acid compounds

Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

Antibodies binding to α7β1 integrin antibodies and compositions thereof

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Growing community of inventors

Oakland, CA, United States of America

Scott Turner